Mantell Associates

New opportunity! CFO - Pharma - UK. Mantell Associates is currently partnered with an innovative Dermatology company who is searching for a Chief Financial Officer (CFO) to join their leadership team and drive the company forward. Apply for this role online - https://lnkd.in/g9nVxziK - or contact George Hebden Lee on +44 (0)20 3854 7700. #financejobs #cfo #pharmajobs

Georgia Read discusses how the integration of computational biology, AI, and ML is revolutionising drug discovery, offering unprecedented speed and precision in identifying and developing new therapeutics. Read more below: https://lnkd.in/ePfVx8q7 #ai #drugdiscovery #computationalbiology

QIAGEN has expanded its cell and gene therapy portfolio with an enhanced dPCR workflow that includes solutions for lentivirus-based applications, commonly used in the production of advanced treatments such as CAR-T, a personalized form of cancer immunotherapy. Read more below: https://lnkd.in/ec7SYqwW #lentivirus #expansion #cellandgene

Working on this recent search with Polpharma Biologics, appointing Anjan Selz as Managing Director Switzerland AG, was yet another fantastic Senior achievement for Mantell Associates! Anjan is a seasoned leader with over 20 years of experience in the Pharma and Biosimilars space. His focus lies on leadership through empowerment, creating an environment where individuals and teams can excel and deliver their best ever performance. Mantell Associates shortlisted 42 potential high-level candidates down to a final 20 in 14 working days. It was a pleasure working with all at Polpharma Biologics and we look forward to our continued partnership! #appointments #biologics #biosimilars

Novartis has committed another $1.7 billion to its ambition to become a kidney disease leader. The Swiss drugmaker is making the outlay, around half of which is upfront, to buy Regulus Therapeutics for a rare renal disease drug that is set to enter phase 3 in the third quarter. Read more below: https://lnkd.in/gziRiKFx #kidneydisease #pharmainvestment #drugdevelopment

AstraZeneca has axed three MedImmune legacy monoclonal antibody drugs from its neuroscience pipeline in a first-quarter clear-out. Read more below: https://lnkd.in/dUgEwjQf #neuroscience #antibodies #alzheimers

Don't just listen to us, listen to what our clients and candidates have to say about us... "I would like to recommend Conor O'Shea and #MantellAssociates, who played a key role in securing my new position. His expertise, network, and tailored guidance made the entire process seamless - resulting in a perfect career match. Professional, proactive, and highly effective. A true asset for a candidate in Life Science and Pharmaceutical firms..." Contact Conor O'Shea on +44 (0)20 3854 7700. #testimonialtuesday #cdmojobs #qualityjobs

Dutch biotech Prilenia Therapeutics has entered a licensing pact with Spanish pharmaceutical company Ferrer to push the biotech's sole asset through clinical development and beyond in Europe. Read more below: https://lnkd.in/gnA4299v #biotechnews #clinical #neurodegenerative

While much of the conversation around the Trump administration’s potential pharmaceutical import tariffs has leaned heavily toward branded drugmakers, generic medicines and the companies that manufacture them will be uniquely vulnerable in the event of a trade war given just how “little resilience” the industry enjoys compared to its patented counterpart. Read more below: https://lnkd.in/eBdgV4TF #generics #pharmanews #supplychain

Nearly two years after reporting successful results from a phase 3 trial of its oral version of injected obesity treatment Wegovy, Novo Nordisk has asked the FDA to approve it. Read more below: https://lnkd.in/gzvFB6hf #fda #injectables #fdaapproval